(NASDAQ: CABA) Cabaletta Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 36.37%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.39%.
Cabaletta Bio's earnings in 2025 is -$126,760,000.On average, 12 Wall Street analysts forecast CABA's earnings for 2025 to be -$119,611,638, with the lowest CABA earnings forecast at -$122,082,827, and the highest CABA earnings forecast at -$115,618,156. On average, 11 Wall Street analysts forecast CABA's earnings for 2026 to be -$91,413,696, with the lowest CABA earnings forecast at -$109,402,126, and the highest CABA earnings forecast at -$55,411,466.
In 2027, CABA is forecast to generate -$83,467,327 in earnings, with the lowest earnings forecast at -$124,817,880 and the highest earnings forecast at -$39,960,192.